Immunobiology of human mucin 1 in a preclinical ovarian tumor model

[1]  S. Reinartz,et al.  CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells. , 2012, European journal of cancer.

[2]  I. Shih,et al.  Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.

[3]  D. Roberts,et al.  Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/β-Catenin and PTEN , 2011, PloS one.

[4]  Maxime Pinard,et al.  MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis. , 2011, Gynecologic oncology.

[5]  S. Gendler,et al.  Pancreatic ductal adenocarcinoma mice lacking mucin 1 have a profound defect in tumor growth and metastasis. , 2011, Cancer research.

[6]  A. Vlad,et al.  Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer , 2011, Cancer Immunology and Immunotherapy.

[7]  G. Coukos,et al.  Immunotherapy for ovarian cancer: what's next? , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Allavena,et al.  Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages , 2011, Clinical & developmental immunology.

[9]  H. Ueno,et al.  Recent Developments in Cancer Vaccines , 2011, The Journal of Immunology.

[10]  L. D. White,et al.  Molecular and Functional Characteristics of Ovarian Surface Epithelial Cells Transformed by KrasG12D and loss of Pten in a Mouse Model in vivo , 2011, Oncogene.

[11]  S. Gendler,et al.  MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition , 2010, Oncogene.

[12]  K. K. van de Vijver,et al.  Expression of aberrantly glycosylated Mucin‐1 in ovarian cancer , 2010, Histopathology.

[13]  B. Karlan,et al.  Ovarian cancer: the duplicity of CA125 measurement , 2010, Nature Reviews Clinical Oncology.

[14]  Michel Salzet,et al.  Epithelial-mesenchymal transition in ovarian cancer. , 2010, Cancer letters.

[15]  I. Diaconu,et al.  A conditional mouse model for human MUC1-positive endometriosis shows the presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells , 2009, Disease Models & Mechanisms.

[16]  D. Kufe,et al.  MUC1-C oncoprotein functions as a direct activator of the nuclear factor-kappaB p65 transcription factor. , 2009, Cancer research.

[17]  Martin A. Cheever,et al.  The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research , 2009, Clinical Cancer Research.

[18]  M. Paquet,et al.  Cell type-specific targeted mutations of Kras and Pten document proliferation arrest in granulosa cells versus oncogenic insult to ovarian surface epithelial cells. , 2009, Cancer research.

[19]  J. Gariépy,et al.  Tumor-associated MUC1 glycopeptide epitopes are not subject to self-tolerance and improve responses to MUC1 peptide epitopes in MUC1 transgenic mice , 2009, Biological chemistry.

[20]  R. Weinberg,et al.  Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits , 2009, Nature Reviews Cancer.

[21]  Jinsong Liu,et al.  Epithelial ovarian cancer: Focus on genetics and animal models , 2009, Cell cycle.

[22]  P. Kalinski,et al.  Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines , 2009, Cancer Immunology, Immunotherapy.

[23]  C. Melief.  Cancer immunotherapy by dendritic cells. , 2008, Immunity.

[24]  T. Skaar,et al.  MUC1 Enhances Tumor Progression and Contributes Toward Immunosuppression in a Mouse Model of Spontaneous Pancreatic Adenocarcinoma1 , 2008, The Journal of Immunology.

[25]  P. Sabbatini,et al.  REVIEW ARTICLE: Harnessing the Immune System for Ovarian Cancer Therapy , 2007, American journal of reproductive immunology.

[26]  D. Kufe,et al.  MUC1 oncoprotein activates the IκB kinase β complex and constitutive NF-κB signalling , 2007, Nature Cell Biology.

[27]  G. Zhu,et al.  Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. , 2007, Cancer research.

[28]  A. Sepulveda,et al.  Cutting Edge: Transgenic Expression of Human MUC1 in IL-10−/− Mice Accelerates Inflammatory Bowel Disease and Progression to Colon Cancer1 , 2007, The Journal of Immunology.

[29]  A. Klein-Szanto,et al.  Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. , 2006, The American journal of pathology.

[30]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  J. Boyd.  Mouse models of gynecologic pathology. , 2005, The New England journal of medicine.

[32]  Xiaolong Wei,et al.  Human MUC1 oncoprotein regulates p53-responsive gene transcription in the genotoxic stress response. , 2005, Cancer cell.

[33]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[34]  P. Chu,et al.  Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. , 2004, American journal of clinical pathology.

[35]  R. Bast,et al.  Use of CA-125 in Clinical Trial Evaluation of New Therapeutic Drugs for Ovarian Cancer , 2004, Clinical Cancer Research.

[36]  Robert C. Bast,et al.  Selection of Potential Markers for Epithelial Ovarian Cancer with Gene Expression Arrays and Recursive Descent Partition Analysis , 2004, Clinical Cancer Research.

[37]  A. Thathiah,et al.  MUC1: A multifunctional cell surface component of reproductive tissue epithelia , 2004, Reproductive biology and endocrinology : RB&E.

[38]  A. Flesken-Nikitin,et al.  Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. , 2003, Cancer research.

[39]  Barbara C Vanderhyden,et al.  Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. , 2003, Cancer research.

[40]  L. Otvos,et al.  Complex Carbohydrates Are Not Removed During Processing of Glycoproteins by Dendritic Cells , 2002, The Journal of experimental medicine.

[41]  M. Ghazizadeh,et al.  Expression of MUC1 and MUC2 mucin gene products in human ovarian carcinomas. , 2002, Japanese journal of clinical oncology.

[42]  M. Groszer,et al.  Cre/loxP‐mediated inactivation of the murine Pten tumor suppressor gene , 2002, Genesis.

[43]  D. Kufe,et al.  The c-Src Tyrosine Kinase Regulates Signaling of the Human DF3/MUC1 Carcinoma-associated Antigen with GSK3β and β-Catenin* , 2001, The Journal of Biological Chemistry.

[44]  Simon C Watkins,et al.  The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells1 , 2000, The Journal of Immunology.

[45]  J L Pace,et al.  Development of a syngeneic mouse model for events related to ovarian cancer. , 2000, Carcinogenesis.

[46]  Dongshu Chen,et al.  T cell suppression as a mechanism for tolerance to MUC1 antigen in MUC1 transgenic mice , 2000, Breast Cancer Research and Treatment.

[47]  D. Kufe,et al.  Interaction of Glycogen Synthase Kinase 3β with the DF3/MUC1 Carcinoma-Associated Antigen and β-Catenin , 1998, Molecular and Cellular Biology.

[48]  M. Hollingsworth,et al.  Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. , 1998, Cancer research.

[49]  R. Barth,et al.  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Kufe,et al.  Interaction of the DF3/MUC1 Breast Carcinoma-associated Antigen and β-Catenin in Cell Adhesion* , 1997, The Journal of Biological Chemistry.

[51]  R. Metzgar,et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. , 1994, Cancer research.

[52]  T. Irimura,et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. , 1993, Journal of immunology.

[53]  K. Jerome,et al.  Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. , 1993, Journal of immunology.

[54]  R. Dahiya,et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. , 1993, Cancer research.

[55]  S. Gendler,et al.  Molecular cloning and analysis of the mouse homologue of the tumor-associated mucin, MUC1, reveals conservation of potential O-glycosylation sites, transmembrane, and cytoplasmic domains and a loss of minisatellite-like polymorphism. , 1991, The Journal of biological chemistry.

[56]  N. Peat,et al.  Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. , 1990, The Journal of biological chemistry.

[57]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[58]  I. Diaconu,et al.  MUC1 in endometriosis and ovarian cancer , 2006, Immunologic research.

[59]  M. Matzuk.  Gynecologic diseases get their genes , 2005, Nature Medicine.

[60]  T. Jacks,et al.  Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer , 2005, Nature Medicine.